Abstract
62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have